bluuebunny/crossref_metadata_2025_split huggingface dataset:
P03-129 - A Prospective Randomized Controlled Trial of Paliperidone ER Versus Oral Olanzapine in Patients with Schizophrenia
Authors: Schreiner A. , Korcsog P. , Niehaus D.J.H. , Aadamsoo K. , Uecok A. , Franco M. , Theodoropoulou P. , Salinas R. , Bergmans P. , Hoeben D. , Tessier C. 
Published: June 2010

ObjectiveTo compare the longer-term metabolic effects and efficacy of paliperidone ER and olanzapine in patients with schizophrenia.MethodsProspective 6-month randomized study evaluating flexible doses of paliperidone ER and oral olanzapine (OLA). Primary endpoint was the change in triglyceride to high-density lipoprotein (TG:HDL) ratio, a sensitive measure of insulin resistance. Additional endpoints were the Positive and Negative Syndrome Scale (PANSS), body weight, lipids, homoeostasis model of insulin resistance (HOMA-IR) and adverse events (AEs).Results239 patients were randomized to paliperidone ER, 220 to olanzapine. Demographics and baseline characteristics were comparable. Mean doses were 6.9±1.3 mg/day for paliperidone ER and 11.6±2.3 mg/day for olanzapine. The TG:HDL ratio for olanzapine significantly worsened from baseline to endpoint (0.42±1.19;p< 0.0001); it remained unchanged for paliperidone ER (-0.08±1.10;p=0.4718; between-group difference p< 0.0001). PANSS total scores at endpoint significantly improved (olanzapine -16.6±15.0; paliperidone ER -13.5±15.9; both p< 0.0001 vs. baseline); the between-group difference met prespecified non-inferiority criteria. Endpoint weight change was 3.8±5.9kg for olanzapine and 1.2±4.6kg for paliperidone ER (p< 0.0001). Insulin resistance in HOMA-IR did not change with paliperidone ER (p=0.1507) but significantly worsened with olanzapine (p=0.003 vs. baseline). The most frequently reported treatment-emergent AEs (>=5%) were weight increase (OLA 18.2%;Pali ER 9.6%), insomnia (OLA 1.4%;Pali ER 9.6%), somnolence (OLA 9.5%;Pali ER 3.3%) and schizophrenia (OLA 1.8%;Pali ER 5.0%).ConclusionIn this randomized controlled study paliperidone ER was superior to olanzapine with regards to insulin resistance, weight gain, lipid changes and other relevant metabolic endpoints. Efficacy was non-inferior between paliperidone ER and olanzapine.
P03-133 - First Episode Psychosis and Multiple Sclerosis
Authors: Yelmo S. , Morera-Fumero A. , Díaz-Mesa E. , Barrau V. , Henry M. , Gracia R. 
Published: June 2010

ObjectivesThere is a significant incidence of psychiatric symptoms in patients with multiple sclerosis, the most common after receiving the diagnosis. We describe a man who was admitted for a first episode psychosis and a diagnosis of multiple sclerosis was made moreover.MethodsA 24-year-old man was admitted with a paranoid delusion, auditory hallucinations with emotional response and the believe that their thoughts were being interfered. Blood test and cranial CT were normal. Risperidone was started. He developed ataxia and sensitive disturbances on the right arm. A cranial and spinal cord MRI revealed multiple T2 and FLAIR hyperintense lesions located in supra and infratentorial white matter, lesions in C3, and one lesion in right basal ganglia that enhanced with gadolinium. CSF analysis showed oligoclonals bands. Three years ago the patient had had transient sensitive symtoms. A diagnosis of relapsing-remitting multiple sclerosis was made and was started methyl-prednisolone intravenously. Risperidone was changed for amisulpride 800 mg/day because lack of response. He was discharged after 25 days. Six months later he has attenuated psychotic symptoms without news lesions in MRI. Glatiramer acetate has been started.Results and conclusionsThe most frequent disorder associated to multiple sclerosis is depression (prevalence of 20%). Psychosis is unusual, transient, sometimes as the onset relapse followed by remission. There's evidence of correlation between psychosis in multiple sclerosis and multiple lesions in temporal periventricular area. We suggest that in our case these two disorders are two separated entities since the enhanced lesion does not correpond with clinical findings.
P03-135 - Delta and Gamma EEG Bands as Markers of Left Hypofrontality for Language in Schizophrenia Patients
Authors: Spironelli C. , Stegagno L. , Angrilli A. 
Published: June 2010

ObjectivesSpectral delta and gamma activity were recorded in 17 schizophrenia patients and 17 matched controls to study brain dysfunction/inhibition and functional linguistic impairment in different phases of written word processing.MethodsMost of patients were suffering from paranoid schizophrenia and obtained relatively high rating in Delusions (P1) and Conceptual disorganization (P2) of the PANSS. Delta and gamma amplitudes were measured while participants performed three linguistic tasks, i.e., visuo-perceptual, rhyming and semantic judgment.ResultsCompared with healthy controls, patients showed no overall delta and gamma differences, revealing a lack of pharmacological-dependent impairment. However, ANOVAs revealed bilateral delta and gamma distributions in patients and, compared with controls, significant greater delta and lower gamma levels in left anterior sites. Healthy participants showed higher delta amplitude in right vs. left anterior sites and a reversed pattern for gamma amplitude: delta and gamma provided complementary results which suggested that controls, but not patients, activated left anterior regions during the linguistic processing. Patients’ hypofrontality was functionally correlated to their lack of left hemispheric specialization for language: the higher delta amplitude in left anterior sites, the higher levels of P1 and P2 positive symptoms; the higher gamma percentage in right anterior sites, the higher levels of N4 (i.e. Passive/apathetic social withdrawal).ConclusionsDelta and gamma rhythms are quantitative indices of the amount of neurons engaged in specific cognitive processes and they represent complementary physiological indices of neural inhibition/activation able to measure both the hypofrontality and the functional deficit of language lateralization in schizophrenia patients.
P03-137 - The Impact of Therapeutic Options in First Episode Psychosis
Authors: Stoica I. , Ienciu M. 
Published: June 2010

ObjectiveTo create an image of therapeutic options available for the first episode psychsis and the way these options influence the evolution of patients.Material and methodsThe present study is part of a larger follow-up study on a number of 121 patients with a diagnostic of first episode psychosis admitted in the Timisoara Psychiatric Clinic and The Day Clinic in the Timisoara Mental Health Center between 2003-2006 and prospectively monitored from the moment of their first contact with psychiatric services.ResultsThe average calculated duration of prodrome period and average Duration of Untreated Psychosis (DUP) are similar to the results indicated by most other studies. The results of statistical tests show that: the longest the prodrome, the worse the improvement of illness during course; a longer prodrome is correlated with a higher number of relapses during the patient's illness course and a longer Duration of Untreated Psychosis is likely to lead to an increased severity of illness. Patients’ adherence to treatment is influenced both by the traits of the first psychotic episode and the way the patients perceive the side effects and the general utility of the administered medication.ConclusionsPsychiatrists have to dedicate more time and interest to establishing a therapeutic alliance with their patients with first episode psychosis; an individualized strategy is required to establish the adequate means and ways of intervention before initiating any type of therapy.
P03-143 - Effectiveness of Aripiprazol in Acute Schizophrenia
Authors: Trandafir M.-S. 
Published: June 2010

The study aims to demonstrate the efficacy of aripriprazole in treatment of patients with acute exacerbation of schizophrenia and in acute psychotic episodes.MethodologyThis was an observational, uncontrolled, 4 week inpatient study, conducted at Unit VII, Clinical Hospital of Psychiatry Prof Dr. Alexandru Obregia, Bucharest. We included in the study 31 inpatients that suited the criteria admitted between January and March 2008. Patients received aripriprazol oral for four weeks. The patients received initially 15 mg aripiprazol. When the symptomatically hadn’t responded in 5 to 7 days we added 15 more mg aripiprazol. The group was divided in 2 parts: in one of them the patients received 15 mg in the morning, and in the other 15 mg in the morning and 15 more at noon.Treatment efficacy was assessed using PANSS at baseline and at the end of weeks 2 and 4.The CGI-S was performed at baseline and at the end of weeks 1,4. CGI-I assessments were conducted at the end of weeks 1, 2 and 4.ResultsClinically important change were not noted with regard vital signs measurements and physical examinations.At the end of the study a persons gain weight.ConclusionsThe results of the study suggest that aripriprazole was efficacious safe and well tolerated for patients with acute psychosis - Aripriprazol 30mg/day was. Adverse events were generally mild and not treatment limiting. The majority of patients remain on the 30mg/day dose during the study.
P03-144 Kartagener's Syndrome and Psychotic Disorder: A Case Presentation
Authors: Ceylan M.E. , Maner F. , Ermiş A. , Turkcan A. 
Published: June 2010

ObjectiveKartagener's Syndrome is a rare congenital malformation and characterized by the triad of bronchiectasis, sinusitis, and situs inversus. We presented a case diagnosed as Kartagener's syndrome and psychotic disorder not elsewhere specified.Method and resultsThe case was a male patient, 32 years old, high school educated, married, with two children. He had a history with increasing psychotic symptoms and two times of suicide attempts for the last two months needed hospitalisation. In the psychiatric examination affect was blunted, there were anxiety, fear due to auditive hallusinations and referance delusions, anhedonia, suicidal thoughts and attempts, secondary depression. Psychiatric disorder predominently with auditive hallusinations and social withdrawal had a duration of three years. He was diagnosed as Kartagener's Syndrome when he was nine years old. The patient was treated with haloperidol 20 mg/day, biperiden 5 mg/day, klorpromazin 100 mg/day during hospitalisation. The psychotic symptoms were reduced within third day. On radiography his heart was seen at the right side of his body, there was bronchial dilatation in the medial and inferior lobes of left lung, thickness of walls of bronches and increased peribronchial density.ConclusionWe assume that the biochemical disorder that is the cause of the development of Kartegener Syndrome is related with the genetic location which facilitates the development of psychosis or risk of psychosis.
P03-17 - Nursing Demands of Patients with Schizophrenia with Long Term Maintenance Treatment at Home
Authors: Adomaitienė V. , Taranda V. , Jaras A. , Lygnugarytė A. , Andriuškevičienė L. , Dambrauskienė K. 
Published: June 2010

In the last seven years there has been an increase in the number of schizophrenia disease in Lithuania (in 2002-2369,5; in 2008-2795,65 to 100.000 residents). The length of treatment in residential care is getting shorter because of changing regulations.ObjectiveThe goal of the study to explore nursing demands in patients with schizophrenia disorders with long term maintenance treatment at home.MethodsResearch was carried out in four Kaunas primary mental health centers. We used standardized International Mental Health Quality Of Life Scale (QOL-36) questionnaire implemented by Phillip W. Long (2003). Our group was randomly selected and consisted of 123 patients with schizophrenia aging from 18 to 65 years.ResultsSeveral main problems were disclosed: 46% reduced everyday home activities, 68 % mentioned physical fatigue, apathy- 60%, sleep disorders- 81%, memory and attention disorders- 64%, communication problems- 76%. 25% of respondents had suicidal attempt. There were more suicidal attempts in younger patients than others (p < 0,05). We disclosed statistically confident correlation between disease duration and suicidal attempts (p < 0,05). For the senior patients the most often were communication problems (50%), sleep disorders (55%), memory and attention disorders (53%).ConclusionsThe most frequent nursing demands mentioned by patients are caused by memory and attention disorders, as well as sleep disorders. Those problems most frequently occur among older respondents.
P03-18 - Diagnosis of Psychosis
Authors: Agassi J. 
Published: June 2010

There are two traditional theories about psychosis, Kraeplin's and Freud's. According to Kraeplin it is an idee fixe, which renders fanatics psychotic. This is perceptive but false. According to Freud psychosis is severe neurotisis, and this is refuted by light cases of psychosis (ambulatory) and by severe (certifiable) cases of neurosis. It is admitted in a way when it is admitted that analysis is applicable to neurosis, not as yet to psychosis.The refusal to admit this situation renders the field pseudo-scientific. It sends researchers to seek cures to an undiagnosed disease.Yehuda Fried and Joseph Agassi, Paranoia, a Study in Diagnosis, Boston sstudies in teh Philosophy of Science, volume 50, 1976, is systematically ignored even though Fried was a leading Israeli psychiatrist with some international repute. It is time to admit its criticism of received ideas and hopefully also to discuss critically its alternative proposal. The alternative is indebted to both Kraeplin adn Freud but more so to Henri Ey. It is that in addition to what was said before, the important missing characterization of the disease is that psychotics hold peculiar views that they refuse to admit are peculiar. We also claim that this is clearstin paranoia vera, and that the disintegration that Bleuler noted is a late stage of any psychosis, so that at its root all psychosis is paranoia.
P03-24 - Clinical Experience with Sertindol on Mexican Patients with Schizophrenia Diagnosis
Authors: Arellano A. 
Published: June 2010

The proposal It's been to describe by an oral presentation, a five cases of Mexican women that have the Schizophrenia diagnosis and that were treated with Sertindol (Serlect) between the months of October 2007 to September 2008, one of them were an Subtype disorganized, other one was Paranoid Subtype and the others were and Indiferential continuous subtype, all of them had an early response on the management of the negative and positive symptoms and also recovered cognitive functions in less time using Sertindol than other antipsychotics treatments. Every one participated on a protocol's study with clinical scales like PANSS, BPRS, and had preclinical studies every 2 weeks by the first 2 months and every 4 weeks by the rest of the time.ConclusionsSertindol it's a very good option for the treatment of the schizophrenia patients with antipsychotics. It brings a safety and efficacy medicine that doesn’t have hardly secondary effects and that gives a better quality of life to this patients.
P03-32 - Validation of the French Version of the Personal and Social Performance Scale (PSP)
Authors: Blanc O. , Delgado A. , Lancon C. , Schwan R. , Schürhoff F. , Lesturgeon J.-A. , Thomas P. , Llorca P.M. 
Published: June 2010

ObjectivesThe Personal and Social Performance (PSP) scale is a reliable and valid instrument that utilizes objective parameters for assessment of social functioning in patients with schizophrenia. The aim of this study was to determine the validity and reliability of the French version of PSP in a population of French schizophrenic patients.MethodsPatients with DSM-IV diagnoses of schizophrenia and schizoaffective disorder were recruited and assessed in a cross-sectional design using the PSP, GAF, SOFS, PANSS, CGI severity. Internal consistency for the PSP was obtained and convergent validity was assessed using correlations between PSP, GAF and PANSS factors. Inter-rater reliability was evaluated with intra class correlation coefficient (ICC).Results147 in and out patients, at 5 French sites participated in this study. The Cronbach's alpha coefficient of the PSP was good (alpha=0.77). The PSP showed very good inter rater reliability (ICC = 0.90). Pearson correlation coefficient for association between PSP and GAF (r=0.85) and PSP and SOFS (r=- 0.78).are high proving good convergent validity for PSP. Pearson correlation coefficients are moderate when PSP is correlated with 4 of the five PANSS sub factors (r from -0.43 to -0.48). The anxious and depression factor (r=-0.17) showed low correlation with PSP. Spearman Rank correlation coefficient between PSP and CGI severity was r=-0.72.ConclusionsOur results demonstrate that the PSP scale is a reliable and valid instrument for assessing social functioning of patients with schizophrenia during the course of treatment as well as in acute state.
P03-35 - Somatic Comorbidities in the Schizophrenic Spectrum Pathology
Authors: Bredicean C. , Milin M. , Salva E. , Mihalcea R. , Popovici Z. , Romosan R. 
Published: June 2010

ObjectivesThe purpose of this study is to determine the type of somatic pathology which appears in schizophrenic spectrum psychosis, in a sample of subjects admitted in the Psychiatric Clinic in Timisoara in the year 2008.MethodsThe sample studied contained 158 patients (105 with a diagnosis of schizophrenia, 46 with schizoaffective disorder and 7 with acute and transitory psychotic disorder) who were admitted in the year 2008. This sample was evaluated from a clinical (PANSS), global functioning (GAF) and somatic co morbidities perspective.ResultsThe case evaluatian showed that 30% of the patients presented also somatic pathology. High incidence presented cardiovascular pathology (8,86%), digestive pathology (7,59%) and respiratory pathology (3,79). Obesity was present in 6,32% of the subjects. There was a category of subjects who presented various types of somatic comorbidities (8,22%).ConclusionsSubjects with psychotic disorders present a high risc for developing somatic pathology, the most common being the cardiovascular pathology. There was no evidence for differencies in the type of somatic pathology between subjects with schizophrenia and those with schizoaffective disorder.
P03-36 - A new Neurocognitive Scale for Schizophrenia Which Could be Used in Daily Practice
Authors: Bretel F. , Opolczynski G. , Cognard C. , Soyer C. , Birien G. , Bourgeois V. , Franck N. , Haouzir S. , Guillin O. 
Published: June 2010

BackgroundNeurocognition is impaired in patients with schizophrenia, and almost all patients demonstrate some measure of decline from their expected level. Neurocognitive impairment is a core feature of schizophrenia and is the single strongest correlate of real-world functioning. To date, several instruments can measure neurocognition, but none of them could be used in daily clinical practice because of their long duration of assessment or the high level of training needed to use them. The aim of the present study was to create a scale that measures different neurocognitive domains usually impaired in schizophrenia (attention, work memory, verbal memory and executive functions).Method and results40 patients with schizophrenia according to DSM-IV-TR criteria have been included in the study and 100% of the patients have been able to complete the scale, that was generally well accepted. Neurocognition was also evaluated in some of the patients with the WAIS-III to compare the scores with our new and not validated scale. Psychiatrists, neuropsychologists and ergotherapists administered the scale. Inter-ratter reliability was evaluated. The time to complete the scale was not more than 10 minutes. Results are under analysis and will be presented during the meeting.ConclusionMeasuring neurocognition in daily practice is crucial to better evaluate the effect on neurocognition of pharmacological and none pharmacological cares in schizophrenia.
P03-37 - Testing A New Technique for the Rehabilitation of Schizophrenia and Other Psychoses Based on Viewing Fiction Films
Authors: Caballero Martínez L. , Magariños M. , Pelaez C. , García del Castillo I. , Calero R. , Mateo I. , Diaz R. , Baca E. , Torre-Marin C. , Luz Chimeno de la Vega M. 
Published: June 2010

Fiction films offer unexplored opportunities of rehabilitation for schizophrenia and other psychoses. Schizophrenia produces deficits y distortions in the perception and comprehension of reality, also expressed in the perception and comprehension of films. After a year of an “ad hoc” experience, the following technique was developed:1)Selecting a fiction film for its narrative, affective, cognitive and social cognitive content2)Briefly presenting of the film to a group of 8-16 patients with diverse psychosis.3)Screening of the film to the patients and the therapeutic team.4)Summarizing of the plot by a patient. Group correcting of distortions and deficits caused by problems of attention and working memory, as well as positive, negative, affective and social cognitive symptoms (emotional perception, theory of mind, attributive style)5)Selecting 1-2 sequences by each patient, and group commenting using the same technique.6)Field recording of all the commentaries obtained.7)Second screening of the film two days after, repeating points 2 to 6.8)Comparing both field records.An experimental study using this technique is presented. 8 patients with schizophrenia and other psychoses watched 4 fiction films (“The 39 Steps”, “Charade”, “M”, “The General”). The differences founded in both viewings by two external evaluators (using CGI and analogical scales of the main variables) are presented and commented. An evaluation of the perceived usefulness and satisfaction of the participants was included.
P03-39 - Consistency of Syndromes of Schizophrenia in Course of 12 Years Follow Up Study
Authors: Cechnicki A. , Franczyk- Glita J. , Cichocki L. 
Published: June 2010

SummaryA group of 80 patients with diagnosis of schizophrenia was followed up in 1, 3, 7 and 12 years after their first psychiatric hospitalization. Their psychopathological status was investigated with BPRS - E scale. Objectives were to identify syndromes measured by BPRS - E scale and to analyze changes in syndromes’ consistency in the course of a 12 years prospective study. Four syndromes were found: positive, negative, depressive and excitement. However, in the following time points, consistency of syndromes was different. The most consistent syndrome was the negative one. Of ten symptoms connected with this syndrome four, namely: motor retardation, blunted affect, uncooperativeness, emotional withdrawal, were present in every follow - up within this syndrome. In the case of the excitement syndrome two symptoms (hostility and tension) were present in all follow - ups. None of the symptoms included in the depressive and positive syndromes were consistently present within these syndromes over the period of twelve years.